About
Today, doctors have two tests – eGFR and UACR – to diagnose whether kidney disease is present in a given patient and at what stage. They do not, however, have a way to predict which patients are at higher vs lower risk for rapid disease progression or kidney failure.
That changes now.
Introducing KidneyIntelX, a laboratory-developed test (LDT), validated in two large cohorts to be a highly-reliable, bioprognosticTM methodology, that yields a simple-to-understand, custom risk score, predicting which adult patients with type 2 diabetes and with chronic kidney disease stages 1-3b are at low, intermediate or high risk for rapid progressive decline in kidney function.
This product is intended for
- Primary Care Physician
- Endocrinologist
- Cardiologist
- Healthcare Provider
- Chief Medical Officer
- Healthcare Administrator
- Physician Assistant
- Diabetes Care Specialist
- Nephrologist
- Advanced Practice Nurse